Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Pharmacological Reviews
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Pharmacological Reviews

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit Pharm Rev on Facebook
  • Follow Pharm Rev on Twitter
  • Follow ASPET on LinkedIn
Review ArticleReview Article

Tumor Necrosis Factor-Induced Cerebral Insulin Resistance in Alzheimer's Disease Links Numerous Treatment Rationales

Ian Clark, Craig Atwood, Richard Bowen, Gilberto Paz-Filho and Bryce Vissel
David R. Sibley, ASSOCIATE EDITOR
Pharmacological Reviews October 2012, 64 (4) 1004-1026; DOI: https://doi.org/10.1124/pr.112.005850
Ian Clark
Research School of Biology, Australian National University, Canberra, Australia (I.C.); Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin (C.A.); School of Exercise, Biomedical and Health Sciences, Edith Cowan University, Joondalup, Australia (C.A.); OTB Research, Charleston, South Carolina (R.B.); John Curtin School of Medical Research, Australian National University, Canberra, Australia (G.P.-F.); and the Neurodegeneration Research Group, Garvan Institute of Medical Research, Sydney, Australia (B.V.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Craig Atwood
Research School of Biology, Australian National University, Canberra, Australia (I.C.); Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin (C.A.); School of Exercise, Biomedical and Health Sciences, Edith Cowan University, Joondalup, Australia (C.A.); OTB Research, Charleston, South Carolina (R.B.); John Curtin School of Medical Research, Australian National University, Canberra, Australia (G.P.-F.); and the Neurodegeneration Research Group, Garvan Institute of Medical Research, Sydney, Australia (B.V.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard Bowen
Research School of Biology, Australian National University, Canberra, Australia (I.C.); Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin (C.A.); School of Exercise, Biomedical and Health Sciences, Edith Cowan University, Joondalup, Australia (C.A.); OTB Research, Charleston, South Carolina (R.B.); John Curtin School of Medical Research, Australian National University, Canberra, Australia (G.P.-F.); and the Neurodegeneration Research Group, Garvan Institute of Medical Research, Sydney, Australia (B.V.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gilberto Paz-Filho
Research School of Biology, Australian National University, Canberra, Australia (I.C.); Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin (C.A.); School of Exercise, Biomedical and Health Sciences, Edith Cowan University, Joondalup, Australia (C.A.); OTB Research, Charleston, South Carolina (R.B.); John Curtin School of Medical Research, Australian National University, Canberra, Australia (G.P.-F.); and the Neurodegeneration Research Group, Garvan Institute of Medical Research, Sydney, Australia (B.V.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bryce Vissel
Research School of Biology, Australian National University, Canberra, Australia (I.C.); Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin (C.A.); School of Exercise, Biomedical and Health Sciences, Edith Cowan University, Joondalup, Australia (C.A.); OTB Research, Charleston, South Carolina (R.B.); John Curtin School of Medical Research, Australian National University, Canberra, Australia (G.P.-F.); and the Neurodegeneration Research Group, Garvan Institute of Medical Research, Sydney, Australia (B.V.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David R. Sibley
Research School of Biology, Australian National University, Canberra, Australia (I.C.); Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin (C.A.); School of Exercise, Biomedical and Health Sciences, Edith Cowan University, Joondalup, Australia (C.A.); OTB Research, Charleston, South Carolina (R.B.); John Curtin School of Medical Research, Australian National University, Canberra, Australia (G.P.-F.); and the Neurodegeneration Research Group, Garvan Institute of Medical Research, Sydney, Australia (B.V.)
Roles: ASSOCIATE EDITOR
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Information

vol. 64 no. 4 1004-1026
DOI 
https://doi.org/10.1124/pr.112.005850
PubMed 
22966039

Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0031-6997
Online ISSN 
1521-0081
History 
  • Published online September 28, 2012.

Article Versions

  • Earlier version (September 10, 2012 - 11:01).
  • You are viewing the most recent version of this article.
Copyright & Usage 
© 2012 by The American Society for Pharmacology and Experimental Therapeutics

Author Information

  1. Ian Clark,
  2. Craig Atwood,
  3. Richard Bowen,
  4. Gilberto Paz-Filho, and
  5. Bryce Vissel
  1. Research School of Biology, Australian National University, Canberra, Australia (I.C.); Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin (C.A.); School of Exercise, Biomedical and Health Sciences, Edith Cowan University, Joondalup, Australia (C.A.); OTB Research, Charleston, South Carolina (R.B.); John Curtin School of Medical Research, Australian National University, Canberra, Australia (G.P.-F.); and the Neurodegeneration Research Group, Garvan Institute of Medical Research, Sydney, Australia (B.V.)
  1. David R. Sibley, ASSOCIATE EDITOR
  1. Address correspondence to:
    Prof. Ian Clark, Division of Medical Science and Biochemistry, Research School of Biology, Australian National University, Canberra ACT 0200, Australia. E-mail: ian.clark{at}anu.edu.au
View Full Text

Statistics from Altmetric.com

Article usage

Article usage: January 2018 to November 2023

AbstractFullPdf
Jan 2018103544
Feb 2018114422
Mar 20181110031
Apr 20181044524
May 201809814
Jun 201807312
Jul 201846511
Aug 2018214714
Sep 201875923
Oct 201847025
Nov 201847028
Dec 2018871311
Jan 20195852
Feb 20198133
Mar 20198212
Apr 20196323
May 20194613
Jun 20195418
Jul 20192334
Aug 20193100
Oct 20194152
Nov 20196734
Dec 20194610
Jan 20203400
Feb 20204344
Mar 20202921
May 20203731
Jun 20204011
Jul 20202300
Aug 20201824
Sep 20203851
Oct 20206101
Nov 20204910
Dec 20207422
Jan 20217152
Feb 20216027
Mar 20213846
Apr 20214131
May 20218634
Jun 20214344
Jul 202111233
Aug 202110921
Sep 20213142
Oct 20215031
Nov 20213633
Dec 20215130
Jan 20223721
Feb 20224684
Mar 20223332
Apr 20222520
May 20225121
Jun 20223032
Jul 20223043
Aug 20223421
Sep 20223620
Oct 20222521
Nov 20225431
Dec 20222931
Jan 20233421
Feb 20235053
Mar 20235832
Apr 20233117
May 20232524
Jun 20232210
Jul 20233324
Aug 20231654
Sep 20233810
Oct 20237034
Nov 202386712

PreviousNext
Back to top

In this issue

Pharmacological Reviews: 64 (4)
Pharmacological Reviews
Vol. 64, Issue 4
1 Oct 2012
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Pharmacological Reviews article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Tumor Necrosis Factor-Induced Cerebral Insulin Resistance in Alzheimer's Disease Links Numerous Treatment Rationales
(Your Name) has forwarded a page to you from Pharmacological Reviews
(Your Name) thought you would be interested in this article in Pharmacological Reviews.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Review ArticleReview Article

TNF CAUSES INSULIN RESISTANCE: IMPLICATIONS FOR AD

Ian Clark, Craig Atwood, Richard Bowen, Gilberto Paz-Filho and Bryce Vissel
Pharmacological Reviews October 1, 2012, 64 (4) 1004-1026; DOI: https://doi.org/10.1124/pr.112.005850

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Review ArticleReview Article

TNF CAUSES INSULIN RESISTANCE: IMPLICATIONS FOR AD

Ian Clark, Craig Atwood, Richard Bowen, Gilberto Paz-Filho and Bryce Vissel
Pharmacological Reviews October 1, 2012, 64 (4) 1004-1026; DOI: https://doi.org/10.1124/pr.112.005850
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • I. Introduction
    • II. Gonadotropins, Sex Steroids, Tumor Necrosis Factor, and Alzheimer's Disease
    • III. Tumor Necrosis Factor and Alzheimer's Disease
    • IV. Tumor Necrosis Factor, Amyloid β, and τ
    • V. Insulin
    • VI. Tumor Necrosis Factor and Glycogen Synthase Kinase-3
    • VII. Tumor Necrosis Factor and Mitochondrial Dysfunction
    • VIII. Tumor Necrosis Factor and Progenitor Cells
    • IX. Streptozotocin
    • X. The Broader Picture—Stroke, Traumatic Brain Injury, and Infectious Disease
    • XI. Therapeutic Implications
    • XII. Conclusions
    • Authorship Contributions
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Pathways for nonhormonal male contraceptive development
  • The SLC6A15-SLC6A20 neutral amino acid transporter subfamily
  • Microbiota and pain perception in Parkinson's Disease
Show more Review Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Pharmacological Reviews
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacology Research & Perspectives
ISSN 1521-0081 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics